1. Home
  2. MINE vs KRRO Comparison

MINE vs KRRO Comparison

Compare MINE & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mayfair Gold Corp. Common Shares

MINE

Mayfair Gold Corp. Common Shares

N/A

Current Price

$2.52

Market Cap

163.8M

Sector

Energy

ML Signal

N/A

Logo Korro Bio Inc.

KRRO

Korro Bio Inc.

HOLD

Current Price

$12.17

Market Cap

187.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MINE
KRRO
Founded
2019
2014
Country
Canada
United States
Employees
9
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
163.8M
187.9M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
MINE
KRRO
Price
$2.52
$12.17
Analyst Decision
Buy
Analyst Count
0
12
Target Price
N/A
$34.80
AVG Volume (30 Days)
24.1K
293.6K
Earning Date
05-06-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$6,392,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
181.46
52 Week Low
$2.16
$5.20
52 Week High
$4.45
$55.89

Technical Indicators

Market Signals
Indicator
MINE
KRRO
Relative Strength Index (RSI) 46.69 43.54
Support Level $2.16 $10.32
Resistance Level $2.87 $14.78
Average True Range (ATR) 0.19 1.13
MACD 0.02 -0.24
Stochastic Oscillator 37.50 17.53

Price Performance

Historical Comparison
MINE
KRRO

About MINE Mayfair Gold Corp. Common Shares

Mayfair Gold Corp is a mineral exploration company that is engaged in the acquisition and exploration of mineral properties. It has one material mineral property, the Fenn-Gib Gold Property, located in the Guibord, Munro, Michaud, and McCool Townships in northeast Ontario, which is in the exploration stage.

About KRRO Korro Bio Inc.

Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.

Share on Social Networks: